Smith & Nephew Share Discussion Threads

[basildublin] 12/8/2021 10:49

Ian, when S&N say the numbers are the
correct interpretation of the guidance
it gives a certain validity to the figures.

[ianood] 12/8/2021 10:18

Thank you, nothing wrong with doing your own research particularly when you can justify the end result to your own satisfaction.

[basildublin] 12/8/2021 08:32

Ian I am a CA
I took the information supplied with H2
Accounts, asked questions of S&N, got prompt replies, finished up with Trading Profits
between +37% and +49% over 2020 to which they agreed. Simple !
DYOR

[ianood] 11/8/2021 23:33

Basil, thank you. Please what research does that pertain to?

[basildublin] 11/8/2021 20:26

Hold on to your S&N shares.
2021 trading profits are projected to rise between 37% and 49%over 2020 !

[ianood] 10/8/2021 22:36

EI, for what it's worth both ops, 3 years apart, were done under an epidural.

I do hold S&N, however, I suspect it may not be for too much longer!

[essentialinvestor] 10/8/2021 17:28

Ian, good to hear of that positive personal experience,
surgery under GA is not an option for me so mine better hold out!.

The posts not intended to deter anyone from buying here,
just for discussion purposes only. Always dyor etc.


Phil, lovely price.

[ianood] 10/8/2021 17:10

EI, Interesting comment, I have 2 Stryker knees installed via their robotic arm system which guarantees precision of 1mm in limb length and <1 degree deviation in the rotation of the knee from the norm. I did think that SN would be a good base from which Stryker could scale up in UK/Europe but now having seen and felt the product results I am thinking why would they bother, it will gravitate to them by results alone! Also the Stryker system makes component parts comparatively easy to replace and therefore not a complete TKR in the extremely rare event of a failure!

[philanderer] 10/8/2021 16:50

Afternoon EI.

Showing my age here but I remember first buying these at 180p . Had them in a 'Single Company' PEP :-)

[essentialinvestor] 10/8/2021 15:45

Look through the director dealing announcements over the last 6 months.
A couple of senior employees in leadership roles appear to have sold and
now don't seem to hold a single share in the Company?.

That being said, now trading at a level I mentioned a few months back as a target price.

There is no comparison with Stryker, it's risible to even mention the two in
the same breath. Stryker's record is exceptional.

Also worth considering some of the broker views, SN. lack a cementless knee product
ATM and this is arguable proving costly.

But ultimately the shares are no where near cheap even at current levels.
Speculative buy at best Imv.

[philanderer] 10/8/2021 12:39

Questor: it’s not immune from inflation but Smith & Nephew is a quality business. Keep buying

Questor share tip: the medical equipment specialist is still recording high-teens operating margins even when it is not quite on top form

[suetballs] 09/8/2021 09:46

imo a good move ygor.
Sold my holding in digs which is currently under offer and invested the proceeds here - more than doubled my holding.
sn. looks good value and tbh I can't see much downside from here.
Suet

[ygor705] 09/8/2021 08:26

Opened a position here this morning. I have been tracking the US equivalent of S&N (Stryker) over the last month or so and its latest numbers published a week or so ago indicated a strong recovery. I do wonder about the quality of the management here but as others have said S&N is a quality business and so even if the current leadership can't run the business properly there are others who can. There has been a big fall here and potential US predators are active.

[andyj] 06/8/2021 10:30

Happy to buy in here at 13.80, there might be further downside, upon which I would add more. This is a quality company in a long term uptrend selling products the world needs and will need in increasing volumes.

[timbo_slice] 06/8/2021 08:55

All her shares! Is she leaving?

[essentialinvestor] 05/8/2021 11:44

Chunky director share sale if I'm reading that correctly/

[spoole5] 03/8/2021 13:18

Essential investor called this right

[finkie] 29/7/2021 14:03

Bought in today at 1470p like the story here results were good will be 1650p plus soon enough gla

[essentialinvestor] 29/7/2021 12:18

..Guidance assumes surgery volumes largely unconstrained by COVID in second half of 2021..


Draw your own conclusions!.


As mentioned back in June there may be better opportunities to add.

Under £14 may be worth a look.

[bigbertie] 29/7/2021 10:43

Well they are recovering, but what a woeful list of "headwinds". No wonder the price has plunged!

[spoole5] 14/7/2021 15:08

Hopefully the results will kick this on

[essentialinvestor] 09/6/2021 14:43

Think there will be better opportunities to add, however very much imv only
and there is always the outside possibility of a bid.

Luck to holders.

[1nf3rn0] 09/6/2021 12:16

Credit Suisse upgraded shares of artificial hip and knee maker Smith & Nephew on Wednesday to 'outperform' from 'neutral', lifting the price target to 1,805p from 1,560p as it pointed to "underappreciated growth drivers".The bank argued that S&N is an underappreciated elective surgery recovery play in the near term and that investors underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid-term.It upped its FY21-23 sales/adjusted earnings per share estimates by an average 2%/6%, leaving it 3%/5% above Bloomberg consensus."As the drivers become clearer gaining the confidence of investors, we expect Smith & Nephew stock to reverse its material underperformance over the past 12 months," Credit Suisse said.The bank noted that since late 2017, Smith & Nephew has bought several bolt-on technologies, committing close to $1.6bn, and with associated negative M&A effects on trading margin of around 150 basis points for FY21."We deep-dived into the potential for the new technologies," it said. "We believe the Wound Biologics/Sports Medicine/Extremities/ENT franchises can add circa 80/15/40/40bps to group underlying growth mid-term."This would turn Smith & Nephew from low-to-mid single digit into mid-to-high single digit underlying growth mode and generate relevant operating leverage, providing upside to trading margin."